Emyria Ltd (ASX:EMD) managing director Michael Winlo runs Proactive through the company’s September quarter highlights. EMD generated $1,034,172 of clinical billings - an increase of more than 250% compared to the previous quarter- supported by the acquisition of The Pax Centre. The company also successfully recruited first patient into its ethics-approved MDMA-assisted therapy program as well as secured a local supply of MDMA to start active dosing.
Emyria hails strong growth in clinical billings
